Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA

H

HKG Epitherapeutics

Status

Terminated

Conditions

Lung Cancer, Small Cell
Lung Cancer, Nonsmall Cell
Lung Cancer

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT03499678
HKG-KZ-LNG-102

Details and patient eligibility

About

A central challenge in the fight against lung cancers is how to detect disease in a noninvasive manner before it is detectable by imaging methods. Although inroads have been made with more sensitive imaging techniques for earlier detection of breast and lung cancers, these techniques are limited by the size of lesion that could be detected. Alternatively, several blood proteomic biomarkers have been proposed but none offer as of yet sufficient predictive power. Consequently, effective non-invasive tools as prognostic indicators and biomarkers of lung cancer is urgently needed. The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in lung cancer patients.

Enrollment

81 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Histological confirmed lung cancer

Exclusion criteria

  • Pregnant women
  • Minors (subjects less than 18 years of age)
  • Prisoners
  • Patients with known infectious disease, such as human immunodeficiency virus (HIV), tuberculosis (TB), or hepatitis B, C
  • Patients having other than one cancer
  • Subjects unable to consent for themselves

Trial design

81 participants in 2 patient groups

Lung Cancer
Description:
Small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC)
Control
Description:
Age and sex matched control individuals

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems